Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.

@article{Mitchell2015ClinicalTP,
  title={Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.},
  author={Aaron Mitchell and Michael R. Harrison and Mark Stephen Walker and Daniel J. George and Amy P Abernethy and Bradford R. Hirsch},
  journal={Journal of oncology practice},
  year={2015},
  volume={11 6},
  pages={491-7}
}
PURPOSE Although narrow eligibility criteria improve the internal validity of clinical trials, they may result in differences between study populations and real-world patients, threatening generalizability. Therefore, we evaluated whether patients treated for metastatic renal cell cancer (mRCC) in routine clinical practice are similar to those enrolled onto… CONTINUE READING